|
|
OECD Series on Adverse Outcome Pathways
From OECD Publishing Contact information at EDIRC. Bibliographic data for series maintained by (). Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.
- 42: Adverse Outcome Pathway on Deposition of Energy Leading to Learning and Memory Impairment
- Ahmad Sleiman, Kathleen Miller, Danicia Flores, Jacqueline Kuan, Kaitlyn Altwasser, Benjamin Smith, Hailey Adams, Tatiana Kozbenko, Robyn Hocking, Carole Yauk, Ruth Wilkins and Vinita Chauhan
- 41: Adverse Outcome Pathway on Deposition of Energy Leading to Occurrence of Bone Loss
- Snehpal Sandhu, Mitchell Keyworth, Syna Karimi-Jashni, Dalya Alomar, Benjamin Smith, Tatiana Kozbenko, Robyn Hocking, Carole Yauk, Ruth C. Wilkins and Vinita Chauhan
- 40: Adverse Outcome Pathway on Deposition of Energy Leading to Cataracts
- Emma Carrothers, Meghan Appleby, Vita Lai, Tatiana Kozbenko, Dalya Alomar, Benjamin Smith, Robyn Hocking, Carole Yauk, Ruth Wilkins and Vinita Chauhan
- 39: Adverse Outcome Pathway on Deposition of Energy Leading to Abnormal Vascular Remodeling
- Tatiana Kozbenko, Nadine Adam, Veronica Grybas, Benjamin Smith, Dalya Alomar, Robyn Hocking, Janna Abdelaziz, Amanda Pace, Carole Yauk, Ruth Wilkins and Vinita Chauhan
- 38: Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity
- Prarthana Shankar and Dan Villeneuve
- 37: Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development
- Prarthana Shankar and Dan Villeneuve
- 36: Adverse Outcome Pathway on Binding to voltage gate sodium channels during development leading to cognitive impairment
- Iris Mangas, Antonio F. Hernandez, Kevin Crofton, Mary Gilbert, Martin Paparella, Anna Price, Tim Shafer, Laura Martino, Martina Panzarea and Andrea Terron
- 35: Adverse Outcome Pathway on Androgen receptor agonism leading to male-biased sex ratio

- Kelvin J. Santana Rodriguez, Daniel L. Villeneuve, Kathleen M. Jensen, Gerald T. Ankley and David H. Miller
- 34: Adverse Outcome Pathway on Aromatase inhibition leading to male-biased sex ratio via impacts on gonad differentiation

- Kelvin J. Santana Rodriguez, Daniel L. Villeneuve, Kathleen M. Jensen, Gerald T. Ankley and David H. Miller
- 33: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis

- Sabina Halappanavar, Monita Sharma, Silvia Solorio-Rodriguez, Hakan Wallin, Ulla Vogel, Kristie Sullivan and Amy J. Clippinger
- 32: Adverse Outcome Pathway on deposition of energy leading to lung cancer

- Samantha Sherman, Zakara Said, Baki Sadi, Carole Yauk, Danielle Beaton, Ruth Wilkins, Robert Stainforth, Nadine Adam and Vinita Chauhan
- 31: Disruption of VEGFR signaling leading to developmental defects

- Thomas B. Knudsen, Katerine Saili, Jill Franzosa, Nancy Baker, Richard Spencer, Tamara Tal, Nicole Kleinstreuer, Tuula Heinonen, Rob Ellis-Hutchings, Neil Vargesson and Maria Bondesson
- 30: Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response

- Yutaka Kimura, Setsuya Aiba, Takao Ashikaga, Takumi Ohishi and Kiyoshi Kushima
- 29: Oxidative DNA damage leading to chromosomal aberrations and mutations

- Eunnara Cho, Ashley Allemang, Marc Audebert, Vinita Chauhan, Stephen Dertinger, Giel Hendriks, Mirjam Luijten, Francesco Marchetti, Sheroy Minocherhomji, Stefan Pfuhler, Daniel J. Roberts, Kristina Trenz and Carole L. Yauk
- 28: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation

- You Song and Daniel L. Villeneuve
- 27: Chitin synthase 1 inhibition leading to mortality

- Simon Schmid, You Song and Knut Erik Tollefsen
- 26: Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation

- Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
- 25: Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation

- Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
- 24: Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation

- Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
- 23: Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation

- Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
- 22: Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation

- Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
- 21: Inhibitor binding to topoisomerase II leading to infant leukaemia

- Olavi Pelkonen, Andrea Terron, Antonio F. Hernandez, Pablo Menendez and Susanne Hougaard Bennekou
- 20: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leading to impairment of learning and memory

- Florianne Tschudi-Monnet, Marie-Gabrielle Zurich, Carolina Nunes, Jenny Sandström, Rex FitzGerald, Michael Aschner and Joao Rocha
- 19: Adverse Outcome Pathway on Cyp2E1 activation leading to liver cancer

- Francina Webster, Iain B. Lambert and Carole L. Yauk
- 18: Adverse Outcome Pathway on inhibition of calcineurin activity leading to impaired T-cell dependent antibody response

- Hiroyuki Komatsu, Junichiro Sugimoto, Ken Goto, Kiyoshi Kushima, Naohisa Tsutsui, Shigeru Hisada, Shiho Ito, Tadashi Kosaka, Takumi Ohishi, Yasuharu Otsubo and Yoshihiro Takahashi
- 17: Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy

- Shihori Tanabe, Akihiko Hirose and Takashi Yamada
- 16: Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF

- Amani Farhat and Sean W. Kennedy
- 15: Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria

- Amani Farhat, Gillian Manning, Jason O’Brien and Sean W. Kennedy
- 14: Adverse Outcome Pathway on inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment

- Alexandra Rolaki, Francesca Pistollato, Sharon Munn and Anna Bal-Price
- 13: Adverse Outcome Pathway on inhibition of Thyroperoxidase and subsequent adverse neurodevelopmental outcomes in mammals

- Kevin M. Crofton, Mary Gilbert, Katie Paul Friedman, Barbara Demeneix, Mary Sue Marty and R. Thomas Zoeller
- 12: Adverse Outcome Pathway on aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2

- Jon Doering, Markus Hecker, Daniel L. Villeneuve and Xiaowei Zhang
- 11: Adverse Outcome Pathway on binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain

- Ping Gong and Edward J. Perkins
- 10: Adverse Outcome Pathway on antagonist binding to PPARα leading to body-weight loss

- Kurt A. Gust, Mitchell S. Wilbanks, Zachary A. Collier, Lyle D. Burgoon and Edward J. Perkins
- 9: Adverse Outcome Pathway on Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish)

- Daniel L. Villeneuve
- 8: Adverse Outcome Pathway on chronic binding of antagonist to N-methyl-D-aspartate receptors during brain development leading to neurodegeneration with impairment in learning and memory in aging

- Florianne Tschudi-Monnet and Rex FitzGerald
- 7: Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits

- Anna Bal-Price, Marcel Leist, Stefan Schildknecht, Florianne Tschudi-Monnet, Alicia Paini and Andrea Terron
- 6: Adverse Outcome Pathway on binding of agonists to ionotropic glutamate receptors in adult brain leading to excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment

- Magdalini Sachana, Sharon Munn and Anna Bal-Price
- 5: Adverse Outcome Pathway on chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities

- Magdalini Sachana, Sharon Munn and Anna Bal-Price
- 4: Adverse Outcome Pathway on Aromatase Inhibition Leading to Reproductive Dysfunction (in Fish)

- Daniel L. Villeneuve
- 3: Adverse Outcome Pathway on Alkylation of DNA in Male Pre-Meiotic Germ Cells Leading to Heritable Mutations

- Carole Yauk, Iain Lambert, Francesco Marchetti and George Douglas
- 2: Adverse Outcome Pathway on Protein Alkylation Leading to Liver Fibrosis

- Brigitte Landesmann
- 1: Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways

- Oecd
|
|
|
|